A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia (CAH)
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Hydrocortisone (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions
- Sponsors Diurnal
- 05 Sep 2017 Planned number of patients changed from 126 to 136.
- 17 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
- 17 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2018.